Subject(s)

Betacoronavirus/pathogenicity , Coronavirus Infections/immunology , Coronavirus Infections/therapy , Flagellin/immunology , Flagellin/therapeutic use , Immunity, Innate/immunology , Neutrophils/immunology , Pneumonia, Viral/immunology , Pneumonia, Viral/therapy , Toll-Like Receptor 5/immunology , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Apoptosis Regulatory Proteins/metabolism , Betacoronavirus/immunology , COVID-19 , Calcium-Binding Proteins/metabolism , Chemotherapy, Adjuvant , Coronavirus Infections/complications , Coronavirus Infections/prevention & control , Deoxyribonuclease I/metabolism , Deoxyribonuclease I/pharmacology , Deoxyribonuclease I/therapeutic use , Flagellin/administration & dosage , Humans , Immunity, Innate/drug effects , Inflammation/complications , Inflammation/immunology , Inflammation/pathology , Influenza A virus/immunology , Interferon-beta/biosynthesis , Interferon-beta/immunology , Interleukin-18/immunology , Mice , Models, Immunological , Neutrophils/drug effects , Neutrophils/metabolism , Pandemics/prevention & control , Peptides/therapeutic use , Pneumonia, Viral/complications , Pneumonia, Viral/prevention & control , Pseudomonas aeruginosa/immunology , Severe acute respiratory syndrome-related coronavirus/immunology , SARS-CoV-2 , Toll-Like Receptor 5/agonists